| answer text |
<p>The UK Health Security Agency is collaborating with medicinal chemists at the School
of Cancer and Pharmaceutical Sciences at Kings College London, to develop new antimicrobials
with novel modes of action for the World Health Organization’s priority pathogens.
A series of compounds which evade efflux-mediated resistance are in development. Early-stage
pre-clinical development has gained support from the National Institute of Allergy
and Infectious Diseases through its Preclinical Services team, for studies on pharmacodynamics
and pharmacokinetics and efficacy.</p><p> </p><p>While it is not usual practice to
ring-fence funds for particular topics or conditions, the National Institute for Health
and Care Research has invested more than £6 million in research into fungal infection.</p>
|
 |
